• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Citizen Petition to the US Food and Drug Administration to Change Prescribing Guidelines: The Metformin Experience.公民向美国食品药品监督管理局提交的关于更改处方指南的请愿书：二甲双胍的案例
Circulation. 2016 Nov 1;134(18):1405-1408. doi: 10.1161/CIRCULATIONAHA.116.023041.
2
Be wary of recommending off-label use of meds.警惕推荐药物的非标签使用。
Adv Nurse Pract. 2001 Feb;9(2):18.
3
Prescription drug products; patient labeling requirements: proposed rule.处方药产品；患者标签要求：拟议规则。
Fed Regist. 1979 Jul 6;44(131 Pt 2):40015-41.
4
The patient package insert--health care provider's friend or foe?
Nurs Homes. 1979 Jul-Aug;28(4):24-5.
5
The FDA Revises Restrictions on Metformin Use in Kidney Impairment.美国食品药品监督管理局修订了对肾功能损害患者使用二甲双胍的限制。
Am J Nurs. 2016 Aug;116(8):22-3. doi: 10.1097/01.NAJ.0000490173.76651.27.
6
From the Food and Drug Administration.
JAMA. 1993 Dec 8;270(22):2669. doi: 10.1001/jama.270.22.2669.
7
MedGuide: at last a long-sought opportunity for patient education about prescription drugs.
JAMA. 1997 Mar 26;277(12):949-50.
8
Getting an extension.
Diabetes Obes Metab. 2002 Mar;4(2):139-40.
9
Legal considerations in off-label medication prescribing.非适应证用药处方中的法律考量
Arch Intern Med. 2002;162(15):1777-9. doi: 10.1001/archinte.162.15.1777.
10
FDA puts restrictions on use of controversial diabetes drug.美国食品药品监督管理局对有争议的糖尿病药物的使用加以限制。
Mayo Clin Womens Healthsource. 2011 Feb;15(2):3.

引用本文的文献

1
Large Language Model GPT-4 Compared to Endocrinologist Responses on Initial Choice of Glucose-Lowering Medication Under Conditions of Clinical Uncertainty.在临床不确定性条件下，大型语言模型GPT-4与内分泌学家关于降糖药物初始选择的反应比较。
Diabetes Care. 2025 Feb 1;48(2):185-192. doi: 10.2337/dc24-1067.
2
Transition Metal-Decorated MgO Nanoclusters as Biosensors and Efficient Drug Carriers for the Metformin Anticancer Drug.过渡金属修饰的氧化镁纳米团簇作为生物传感器和二甲双胍抗癌药物的高效药物载体
ACS Omega. 2023 Mar 15;8(12):11318-11325. doi: 10.1021/acsomega.3c00058. eCollection 2023 Mar 28.
3
Translating Research into Health Policy: The Citizen Petition Experience with the Food and Drug Administration.
Cancer Treat Res. 2022;184:61-73. doi: 10.1007/978-3-031-04402-1_4.
4
Prescriber Uncertainty as Opportunity to Improve Care of Type 2 Diabetes with Chronic Kidney Disease: Mixed Methods Study.《机遇与挑战并存：利用医师不确定性改善慢性肾脏病合并 2 型糖尿病患者的治疗》混合方法研究。
J Gen Intern Med. 2023 May;38(6):1476-1483. doi: 10.1007/s11606-022-07838-1. Epub 2022 Oct 31.
5
Baseline Characteristics and Patient-Reported Outcomes of ADPKD Patients in the Multicenter TAME-PKD Clinical Trial.多中心 TAME-PKD 临床试验中 ADPKD 患者的基线特征和患者报告结局。
Kidney360. 2020 Dec 31;1(12):1363-1372. doi: 10.34067/KID.0004002020.
6
Lactic acidosis incidence with metformin in patients with type 2 diabetes and chronic kidney disease: A retrospective nested case-control study.二甲双胍在 2 型糖尿病合并慢性肾脏病患者中的乳酸酸中毒发生率：一项回顾性巢式病例对照研究。
Endocrinol Diabetes Metab. 2020 Jul 17;4(1):e00170. doi: 10.1002/edm2.170. eCollection 2021 Jan.
7
Should metformin remain the first-line therapy for treatment of type 2 diabetes?二甲双胍是否应继续作为2型糖尿病治疗的一线疗法？
Ther Adv Endocrinol Metab. 2021 Jan 13;12:2042018820980225. doi: 10.1177/2042018820980225. eCollection 2021.
8
Rates of Metformin Use in Stage 3b Chronic Kidney Disease Rose After FDA Label Change.美国食品药品监督管理局（FDA）标签变更后，3b期慢性肾脏病患者使用二甲双胍的比例上升。
J Gen Intern Med. 2021 Oct;36(10):3261-3263. doi: 10.1007/s11606-020-06380-2. Epub 2021 Jan 6.
9
Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?二甲双胍在2型糖尿病现代管理中处于什么地位？
Pharmaceuticals (Basel). 2020 Nov 27;13(12):427. doi: 10.3390/ph13120427.
10
Challenges and Strategies for Inpatient Diabetes Management in Older Adults.老年住院患者糖尿病管理的挑战与策略
Diabetes Spectr. 2020 Aug;33(3):227-235. doi: 10.2337/ds20-0008.

本文引用的文献

1
Petitioning the FDA to Improve Pharmaceutical, Device and Public Health Safety by Ordinary Citizens: A Descriptive Analysis.
PLoS One. 2016 May 12;11(5):e0155259. doi: 10.1371/journal.pone.0155259. eCollection 2016.
2
Potential Impact of Prescribing Metformin According to eGFR Rather Than Serum Creatinine.根据估算肾小球滤过率（eGFR）而非血清肌酐来开具二甲双胍处方的潜在影响。
Diabetes Care. 2015 Nov;38(11):2059-67. doi: 10.2337/dc15-0542. Epub 2015 Aug 25.
3
Metformin in patients with type 2 diabetes and kidney disease: a systematic review.二甲双胍在 2 型糖尿病合并肾脏疾病患者中的应用：系统评价。
JAMA. 2014;312(24):2668-75. doi: 10.1001/jama.2014.15298.
4
Metformin in heart failure.二甲双胍与心力衰竭
Diabetes Care. 2007 Dec;30(12):e129. doi: 10.2337/dc07-1686.

Citizen Petition to the US Food and Drug Administration to Change Prescribing Guidelines: The Metformin Experience.

作者信息

Lipska Kasia J, Flory James H, Hennessy Sean, Inzucchi Silvio E

机构信息

From Section of Endocrinology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT (K.J.L., S.E.I.); Department of Healthcare Policy and Research, Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center, New York, NY (J.H.F.); and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia (S.H.).

出版信息

Circulation. 2016 Nov 1;134(18):1405-1408. doi: 10.1161/CIRCULATIONAHA.116.023041.

DOI:10.1161/CIRCULATIONAHA.116.023041
PMID:27799258
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5147418/
Abstract
摘要